Analyst Price Targets — VNDA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 9:59 am | — | H.C. Wainwright | $21.00 | $6.28 | TheFly | Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright |
| February 23, 2026 11:09 am | — | H.C. Wainwright | $24.00 | $8.48 | TheFly | Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright |
| January 5, 2026 11:05 am | — | H.C. Wainwright | $22.00 | $8.25 | TheFly | Vanda Pharmaceuticals price target raised to $22 from $20 at H.C. Wainwright |
| December 31, 2025 10:04 am | — | Jefferies | $7.50 | $7.03 | TheFly | Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies |
| November 5, 2025 7:42 am | Madison El-Saadi | B.Riley Financial | $11.00 | $4.35 | StreetInsider | B.Riley Starts Vanda Pharmaceuticals (VNDA) at Buy |
| July 11, 2024 6:12 am | Charles Duncan | Cantor Fitzgerald | $11.00 | $5.21 | TheFly | Vanda Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald |
Latest News for VNDA
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment…
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, Massachusetts on Thursday, July 16, 2026.
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), a rare, serious, and progressive inherited neurological disorder. The…
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP). Imsidolimab inhibits interleukin‑36 (IL‑36) receptor signaling,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VNDA.
U.S. House Trading
No House trades found for VNDA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.